17 the potential of secondary metabolites from plants as drugs or leads against protozoan neglected diseases—part iii: in-silico molecular docking investigations

18 host-seeking behaviors of mosquitoes experimentally infected with sympatric field isolates of the human malaria parasite plasmodium falciparum: no evidence for host manipulation

19 duality and complexity of allergic type inflammatory mechanisms in determining the outcome of malaria disease

20 paludismo por plasmodiumvivax: presentación de un caso

21 autophagy in plasmodium, a multifunctional pathway?

22 basic biochemical investigations as rationale for the design of original antimalarial drugs. an example of phospholipid metabolism

23 plasmodium falciparum secretome in erythrocyte and beyond

24 Complex nutrient channel phenotypes despite Mendelian inheritance in a Plasmodium falciparum genetic cross

25 Plasmodium falciparum PFI1625c offers an opportunity to design potent anti-malarials: Biochemical characterization and testing potentials in drug discovery.

26 The search for plasmodium falciparum histidine-rich protein 2/3 deletions in Zambia and implications for plasmodium falciparum histidine-rich protein 2-based rapid diagnostic tests

27 Epidemiology of Plasmodium falciparum infection and drug resistance markers in Ota Area, Southwestern Nigeria

28 Clinical utility of tafenoquine in the prevention of relapse of Plasmodium vivax malaria: a review on the mode of action and emerging trial data

29 Profiles of hematological parameters in Plasmodium falciparum and Plasmodium vivax malaria patients attending Tercha General Hospital, Dawuro Zone, South Ethiopia

30 Prevalence of Plasmodium falciparum antimalarial drug resistance genes in Southeastern Gabon from 2011 to 2014

31 Plasmodium knowlesi malaria: current research perspectives

32 Primaquine double dose for 7 days is inferior to single-dose treatment for 14 days in preventing Plasmodium vivax recurrent episodes in Suriname

33 Assessing parasite clearance during uncomplicated Plasmodium falciparum infection treated with artesunate monotherapy in Suriname

34 Molecular analysis of markers associated with chloroquine and sulfadoxine/pyrimethamine resistance in Plasmodium falciparum malaria parasites from southeastern Côte-d'Ivoire by the time of Artemisinin-based Combination Therapy adoption in 2005

35 Epidemiology of Plasmodium falciparum infection and drug resistance markers in Ota Area, Southwestern Nigeria

36 Epidemiology of Plasmodium falciparum infection and drug resistance markers in Ota Area, Southwestern Nigeria

37 Clinical utility of tafenoquine in the prevention of relapse of Plasmodium vivax malaria: a review on the mode of action and emerging trial data

38 Profiles of hematological parameters in Plasmodium falciparum and Plasmodium vivax malaria patients attending Tercha General Hospital, Dawuro Zone, South Ethiopia

39 Prevalence of Plasmodium falciparum antimalarial drug resistance genes in Southeastern Gabon from 2011 to 2014

40 Plasmodium knowlesi malaria: current research perspectives

41 Multiple-Strain Malaria Infection and Its Impacts on Plasmodium falciparum Resistance to Antimalarial Therapy: A Mathematical Modelling Perspective

42 Primaquine double dose for 7 days is inferior to single-dose treatment for 14 days in preventing Plasmodium vivax recurrent episodes in Suriname

43 Assessing parasite clearance during uncomplicated Plasmodium falciparum infection treated with artesunate monotherapy in Suriname

44 Molecular analysis of markers associated with chloroquine and sulfadoxine/pyrimethamine resistance in Plasmodium falciparum malaria parasites from southeastern Côte-d'Ivoire by the time of Artemisinin-based Combination Therapy adoption in 2005

45 The Impact of Plasmodium Infection on Placental Histomorphology: A Stereological Preliminary Study

46 Socioeconomic Risk Factors for Plasmodium falciparum Infection in Primary School Children in Three Districts of the Volta Region Of Ghana.

47 Development of an HPLC-based guanosine monophosphate kinase assay and application to Plasmodium vivax guanylate kinase

48 Correction: Antigenic cartography of immune responses to Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1).

49 Antigenic cartography of immune responses to Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1).

50 Extracellular vesicles carrying lactate dehydrogenase induce suicide in increased population density of Plasmodium falciparum in vitro

51 Characterization of the accessible genome in the human malaria parasite Plasmodium falciparum.

52 Flexible 3D cell-based platforms for the discovery and profiling of novel drugs targeting Plasmodium hepatic infection.

53 Safety and clinical outcome of experimental challenge of human volunteers with Plasmodium falciparum-infected mosquitoes: an update.

54 Prevalence of Plasmodium falciparum Pfcrt and Pfmdr1 alleles in settings with different levels of Plasmodium vivax co-endemicity in Ethiopia.

55 Anti-malarial activity of the root extract of Euphorbia abyssinica (Euphorbiaceae) against Plasmodium berghei infection in mice.

56 Plasmodium vivax readiness to transmit: implication for malaria eradication.

57 Pregnant Women: An Overlooked Asset to Plasmodium falciparum Malaria Elimination Campaigns?

58 Spatial mapping and prediction of Plasmodium falciparum infection risk among school-aged children in Côte d'Ivoire.

59 Adaptation of Plasmodium falciparum to humans involved the loss of an ape-specific erythrocyte invasion ligand.

60 Aspectos parasitários observados no local inoculado com esporozoitos de Plasmodium Gallinaceum

61 Assessment of the Combined Effect of Epstein–Barr Virus and Plasmodium falciparum Infections on Endemic Burkitt Lymphoma Using a Multiplex Serological Approach

62 Human population, urban settlement patterns and their impact on Plasmodium falciparum malaria endemicity.

63 Infants' Peripheral Blood Lymphocyte Composition Reflects Both Maternal and Post-Natal Infection with Plasmodium falciparum.

64 Synthesis and anti-Plasmodium falciparum evaluation of novel pyrazolopyrimidine derivatives

65 Pan-Plasmodium band sensitivity for Plasmodium falciparum detection in combination malaria rapid diagnostic tests and implications for clinical management.

66 Operational accuracy and comparative persistent antigenicity of HRP2 rapid diagnostic tests for Plasmodium falciparum malaria in a hyperendemic region of Uganda.

67 Persistent histidine-rich protein 2, parasite lactate dehydrogenase, and panmalarial antigen reactivity after clearance of Plasmodium falciparum monoinfection.

68 Persistent ICT malaria P.f/P.v panmalarial and HRP2 antigen reactivity after treatment of Plasmodium falciparum malaria is associated with gametocytemia and results in false-positive diagnoses of Plasmodium vivax in convalescence.

69 Operational accuracy and comparative persistent antigenicity of HRP2 rapid diagnostic tests for Plasmodium falciparum malaria in a hyperendemic region of Uganda

70 Stabilization of chloroquine resistance in vivo of plasmodium falciparum in edea, south cameroon

71 Increase of chloroquine resistance in vivo of plasmodium falciparum over two years in edea, South Cameroon

72 In vivo study of amodiaquine sensitivity of Plasmodium falciparum in the town of Edea (Cameroon)

73 A mathematical model for assessing the effectiveness of controlling relapse in Plasmodium vivax malaria endemic in the Republic of Korea.

74 An Exported Heat Shock Protein 40 Associates with Pathogenesis-Related Knobs in Plasmodium falciparum Infected Erythrocytes

75 Prevalence of afebrile parasitaemia due to Plasmodium falciparum & P. vivax in district Balaghat (Madhya Pradesh): Implication for malaria control

76 Plasma cytokines, chemokines and cellular immune responses in pre-school Nigerian children infected with Plasmodium falciparum

77 Molecular Design and Synthesis of Ivermectin Hybrids Targeting Hepatic and Erythrocytic Stages of Plasmodium Parasites.

78 Mechanisms of invasion from sporozoite and merozoíto of Plasmodium

79 Assessment of Antimalarial Activity against Plasmodium falciparum and Phytochemical Screening of Some Yemeni Medicinal Plants

80 The recognition of proteasomal receptors by Plasmodium falciparum DSK2.

81 Plasmodium falciparum-mediated induction of human CD25Foxp3 CD4 T cells is independent of direct TCR stimulation and requires IL-2, IL-10 and TGFbeta.

82 High resolution melting: a useful field-deployable method to measure dhfr and dhps drug resistance in both highly and lowly endemic Plasmodium populations.

83 Excess Fibrin Deposits Decrease Fetal Weight of Pregnant Mice Infected by Plasmodium berghei

84 Confirmation of Anopheles balabacensis as natural vector of malaria caused by Plasmodium knowlesi inhabits forested areas in Kecamatan Balik Bukit, Western Lampung Regency

85 Protein O-Fucosyltransferase 2 Is Not Essential for Plasmodium berghei Development

86 Novel antimalarial chloroquine- and primaquine-quinoxaline 1,4-di-N-oxide hybrids: Design, synthesis, Plasmodium life cycle stage profile, and preliminary toxicity studies

87 Facile synthesis of vanillin-based novel bischalcones identifies one that induces apoptosis and displays synergy with Artemisinin in killing chloroquine resistant Plasmodium falciparum

88 Synthesis of new 4-Aminoquinolines and evaluation of their in vitro activity against chloroquine-sensitive and chloroquine-resistant plasmodium falciparum

89 Design, economical synthesis and antiplasmodial evaluation of vanillin derived allylated chalcones and their marked synergism with artemisinin against chloroquine resistant strains of Plasmodium falciparum

90 Synthesis and Heme Polymerization Inhibitory Activity (HPIA) Assay of Antiplasmodium of (1)-N-(3,4-Dimethoxybenzyl)-1,10-Phenanthrolinium Bromide from Vanillin

91 The multifaceted histone chaperone RbAp46/48 in Plasmodium falciparum: structural insights, production, and characterization.

92 The clinical and parasitological presentation of Plasmodium falciparum malaria in Uganda is unaffected by HIV-1 infection

93 Plasmodium falciparum and Helminth Coinfection in a Semiurban Population of Pregnant Women in Uganda

94 Augmented antibody response to live attenuated measles vaccine in children with Plasmodium falciparum parasitaemia

95 Plasmodium Falciparum malaria and perinatally acquired human immunodeficiency virus type 1 infection in Kinshasa, Zaire. A prospective, longitudinal cohort study of 587 children

96 Increased frequency of malaria attacks in subjects co-infected by intestinal worms and Plasmodium falciparum malaria

97 Out of Africa: origins and evolution of the human malaria parasites Plasmodium falciparum and Plasmodium vivax

98 Exposure to chloroquine in male adults and children aged 9-11 years with malaria due to Plasmodium vivax

99 Loss of cellular immune reactivity during acute Plasmodium falciparum malaria

100 A Prospective Comparative Study of Knowlesi, Falciparum, and Vivax Malaria in Sabah, Malaysia: High Proportion With Severe Disease From Plasmodium Knowlesi and Plasmodium Vivax But No Mortality With Early Referral and Artesunate Therapy

101 Use of Peroxisome Proliferator-Activated Receptor γ Agonists as Adjunctive Treatment for Plasmodium falciparum Malaria: A Randomized, Double-Blind, Placebo-Controlled Trial

Keyword Connections

Journals

Research Groups

Bibliographies